Update: Making Sense of Mazor’s Rise

The door is opened wider for Mazor’s surgical platform in Europe and shares are up 44% since we recommended the stock.

Chart Update: Abiomed ABMD Rewards the Patient

Traders who were patient with the position can now focus on that 13-week SMA as a trailing stop or even consider the 20-week SMA. Selling at either will still lock in some attractive gains from a low $140s entry.

Uncomman Idea: Heart Health iRhythm IRTC

IRTC is changing the marketplace in terms of cardiac testing. The company is establishing itself at the forefront of wearable healthcare tech.

Uncommon Idea: Heart Healthy Medical Devices Abiomed ABMD

Heart failure and coronary disease are the number one causes of death in the United States. This stock is the clear market leader for heart failure patients in need of high-risk heart procedures.

Uncommon Idea: Cloud-Based Pharma Regulation Veeva VEEV

The Uncommon Idea in Brief Buy Veeva Systems (VEEV) stock for the long term. (Published July 5, 2017) Build a long position between $48 and $52. Add aggressively on a breakout over $52. The Industry Opportunity Meet the compliant cloud. Companies that are highly regulated require cloud platforms customized to meet compliance needs. The Compliant

Uncommon Idea: Medical Robotics Mazor MZOR

This company not only has to prove its robotics is safe, but convinced medical facilities to sink large initial investments to use them. Based on the past several quarters of revenue, it’s been successful.